C. Perry

发表

Bacterial resistance mechanisms as therapeutic targets.

I. Chopra, D. Payne, K. Coleman, 1994, The Journal of antimicrobial chemotherapy.

Dose Selection for Phase III Clinical Evaluation of Gepotidacin (GSK2140944) in the Treatment of Uncomplicated Urinary Tract Infections

A. Barth, E. Dumont, N. Scangarella-Oman, 2022, Antimicrobial agents and chemotherapy.

Phase 2a Pharmacokinetic, Safety, and Exploratory Efficacy Evaluation of Oral Gepotidacin (GSK2140944) in Female Participants with Uncomplicated Urinary Tract Infection (Acute Uncomplicated Cystitis)

A. Barth, E. Dumont, Y. Tao, 2020, Antimicrobial Agents and Chemotherapy.

Microbiological Analysis from a Phase 2 Randomized Study in Adults Evaluating Single Oral Doses of Gepotidacin in the Treatment of Uncomplicated Urogenital Gonorrhea Caused by Neisseria gonorrhoeae

E. Hook, L. Miller, Jianzhong Huang, 2018, Antimicrobial Agents and Chemotherapy.

Efficacy and tolerability of albiglutide versus placebo or pioglitazone over 1 year in people with type 2 diabetes currently taking metformin and glimepiride: HARMONY 5

M. Stewart, P. Home, M. C. Carr, 2015, Diabetes, obesity & metabolism.

Efficacy, Safety, and Tolerability of Gepotidacin (GSK2140944) in the Treatment of Patients with Suspected or Confirmed Gram-Positive Acute Bacterial Skin and Skin Structure Infections

W. O'Riordan, Teri Ashton, E. Dumont, 2017, Antimicrobial Agents and Chemotherapy.

Design of Two Phase III, Randomized, Multicenter Studies Comparing Gepotidacin with Nitrofurantoin for the Treatment of Uncomplicated Urinary Tract Infection in Female Participants

Salim Janmohamed, E. Dumont, A. Raychaudhuri, 2022, Infectious Diseases and Therapy.

The antimicrobial activity of mupirocin--an update on resistance.

B. Slocombe, C. Perry, 1991, The Journal of hospital infection.

In Vitro Activity and Microbiological Efficacy of Gepotidacin from a Phase 2, Randomized, Multicenter, Dose-Ranging Study in Patients with Acute Bacterial Skin and Skin Structure Infections

James R. Brown, S. Van Horn, L. Miller, 2019, Antimicrobial Agents and Chemotherapy.

Pharmacokinetic, Safety, and Tolerability Evaluations of Gepotidacin (GSK2140944) in Healthy Japanese Participants

A. S. Gross, A. Barth, S. Shabbir, 2022, Clinical pharmacology in drug development.

Gepotidacin for the Treatment of Uncomplicated Urogenital Gonorrhea: A Phase 2, Randomized, Dose-Ranging, Single-Oral Dose Evaluation

A. Avery, K. Workowski, E. Dumont, 2018, Clinical Infectious Diseases.

Comparison between physiologically based pharmacokinetic and population pharmacokinetic modelling to select paediatric doses of gepotidacin in plague

Rajendra Singh, A. Barth, E. Dumont, 2021, British journal of clinical pharmacology.

High-level mupirocin resistance in Staphylococcus aureus: evidence for two distinct isoleucyl-tRNA synthetases

J. Gilbart, J Gilbart, C R Perry, 1993, Antimicrobial Agents and Chemotherapy.

Efficacy and safety of once-weekly GLP-1 receptor agonist albiglutide (HARMONY 2): 52 week primary endpoint results from a randomised, placebo-controlled trial in patients with type 2 diabetes mellitus inadequately controlled with diet and exercise

M. Nauck, Fred Yang, M. Stewart, 2015, Diabetologia.

Efficacy and safety of once‐weekly glucagon‐like peptide 1 receptor agonist albiglutide (HARMONY 1 trial): 52‐week primary endpoint results from a randomized, double‐blind, placebo‐controlled trial in patients with type 2 diabetes mellitus not controlled on pioglitazone, with or without metformin

J. Reusch, M. Stewart, R. Reinhardt, 2014, Diabetes, obesity & metabolism.

HARMONY 4: randomised clinical trial comparing once-weekly albiglutide and insulin glargine in patients with type 2 diabetes inadequately controlled with metformin with or without sulfonylurea

R. Pratley, M. Stewart, M. C. Carr, 2014, Diabetologia.

Using rapid point-of-care tests to inform antibiotic choice to mitigate drug resistance in gonorrhoea

Tatum D. Mortimer, R. Anderson, Y. Grad, 2020, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

Dose selection for a phase III study evaluating gepotidacin (GSK2140944) in the treatment of uncomplicated urogenital gonorrhoea

E. Dumont, B. Swift, N. Scangarella-Oman, 2022, Sexually Transmitted Infections.

Pharmacokinetics of Oral Formulations of Gepotidacin (GSK2140944), a Triazaacenaphthylene Bacterial Type II Topoisomerase Inhibitor, in Healthy Adult and Adolescent Participants

A. Barth, E. Dumont, C. Perry, 2021, Antimicrobial agents and chemotherapy.

Microbiome recovery in adult females with uncomplicated urinary tract infections in a randomised phase 2A trial of the novel antibiotic gepotidacin (GSK140944)

James R. Brown, Andrea Nuzzo, S. Van Horn, 2021, BMC Microbiology.

Clinical Assessment of Gepotidacin (GSK2140944) as a Victim and Perpetrator of Drug-Drug Interactions via CYP3A Metabolism and Transporters.

A. Barth, S. Shabbir, E. Dumont, 2023, Clinical and translational science.

731. Pharmacokinetics of Gepotidacin (GSK2140944) in Subjects with Hepatic Impairment

E. Dumont, Y. Tao, J. Hands, 2019, Open Forum Infectious Diseases.

O05.3 A phase ii, randomised, study in adult subjects evaluating the efficacy, safety, and tolerability of single doses of gepotidacin (GSK2140944) for treatment of uncomplicated urogenital gonorrhoea

E. Dumont, A. Raychaudhuri, C. Perry, 2017, Sexually Transmitted Infections.

HARMONY 3: 104-Week Randomized, Double-Blind, Placebo- and Active-Controlled Trial Assessing the Efficacy and Safety of Albiglutide Compared With Placebo, Sitagliptin, and Glimepiride in Patients With Type 2 Diabetes Taking Metformin

M. Feinglos, B. Ahrén, Fred Yang, 2014, Diabetes Care.

Albiglutide Does Not Prolong QTc Interval in Healthy Subjects: A Thorough ECG Study

B. Darpo, R. Reinhardt, M. Young, 2014, Diabetes Therapy.

52-week efficacy of albiglutide vs placebo and vs pioglitazone in triple therapy (background metformin and glimepiride) in patients with type 2 diabetes: HARMONY 5 study

P. Home, Fred Yang, M. Stewart, 2013 .

Erratum to: Albiglutide Does Not Prolong QTc Interval in Healthy Subjects: A Thorough ECG Study

B. Darpo, R. Reinhardt, M. Young, 2014, Diabetes Therapy.

Efficacy and Safety of Gepotidacin as Treatment of Uncomplicated Urogenital Gonorrhea (EAGLE-1): Design of a Randomized, Comparator-Controlled, Phase 3 Study

David Bruce Lewis, N. Scangarella-Oman, C. Jakielaszek, 2023, Infectious Diseases and Therapy.